BioMarin posts $1.025 billion in Q3 revenue, a 32% jump, but tempers full-year expectations due to order timing volatility and R&D investment costs.
BioMarin delivered a strong financial performance in Q3 2026 with total revenues reaching $1.025 billion, representing a 32% year-over-year increase. This growth was primarily fueled by a 44% surge in the Metabolic Conditions segment and a 12% rise in Skeletal Conditions. However, the company has adjusted its full-year 2026 guidance to account for order timing uncertainties and the financial impact of recent In-process Research and Development (IPR&D) acquisitions.
The growth was primarily driven by a 44% increase in the Metabolic Conditions segment and a 12% increase in the Skeletal Conditions segment.
The guidance was updated to reflect uncertainty surrounding order timing and the impact of costs associated with two acquired In-process Research and Development (IPR&D) projects.
BioMarin Pharmaceutical reported a robust 32% year-over-year revenue increase to $1.025 billion in the third quarter of 2026, fueled by strong performance in its metabolic and skeletal condition portfolios. Despite the top-line growth, the company adjusted its full-year 2026 guidance to account for order timing uncertainties and the financial impact of recent in-process research and development acquisitions.
The company revised its outlook to account for uncertainty regarding the timing of customer orders and the financial impact of recent in-process research and development (IPR&D) acquisitions.